Teva Pharmaceutical Indus Analyst Price Targets

Wall Street analyst price targets and consensus rating for Teva Pharmaceutical Indus (TEVA).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$40Upside to Avg. PT-2.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$40→$50
Oct 1, 2026	TD Cowen	Joseph Thome	Initiate	Buy	$55
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$50
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Outperform	$45
Sep 4, 2026	UBS	Ashwani Verma	PT Raise	Buy	$42→$48
Aug 12, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$40→$42
Jul 28, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$44
May 6, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$38→$40
Apr 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$35→$40
Apr 30, 2026	UBS	Ashwani Verma	PT Raise	Buy	$36→$42
Apr 30, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$41→$42
Apr 30, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$42→$45
Apr 9, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$38→$42
Mar 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$40→$41
Feb 18, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$38→$42
Feb 9, 2026	Goldman Sachs	Matt Dellatorre	PT Raise	Buy	$36→$45
Jan 30, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$35→$38
Jan 29, 2026	Scotiabank	Louise Chen	PT Raise	Sector Outperform	$35→$40
Jan 29, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$36→$38
Jan 6, 2026	Jefferies	Glen Santangelo	PT Raise	Buy	$29→$40

More with Benzinga EdgeGet Access

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.

Avi Kapoor

PRO
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55

TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $55.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.

Benzinga Newsdesk

Teva Pharmaceutical Industries Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Teva Pharmaceutical Indus Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55

PRO
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

PRO
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

People Also Watch

People Also Watch

Teva Pharmaceutical Industries Ltd

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Teva Pharmaceutical Indus Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROTD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55

PROOppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

PROLeerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

PROUBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PROBarclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

People Also Watch

People Also Watch

PRO
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55

PRO
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

PRO
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45

PRO
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

PRO
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42